National Research (NASDAQ:NRC) Hits New 12-Month Low at $35.75

National Research Co. (NASDAQ:NRC - Get Free Report)'s share price reached a new 52-week low during trading on Wednesday . The company traded as low as $35.75 and last traded at $35.75, with a volume of 10603 shares changing hands. The stock had previously closed at $36.91.

Analysts Set New Price Targets

Separately, TheStreet lowered National Research from a "b-" rating to a "c+" rating in a research note on Thursday, January 11th.

National Research Price Performance

The company has a market capitalization of $844.53 million, a price-to-earnings ratio of 28.33 and a beta of 0.42. The company has a current ratio of 0.67, a quick ratio of 0.67 and a debt-to-equity ratio of 0.60. The company's 50 day simple moving average is $39.09 and its 200-day simple moving average is $40.63.

National Research (NASDAQ:NRC - Get Free Report) last posted its quarterly earnings data on Tuesday, February 13th. The company reported $0.36 earnings per share (EPS) for the quarter. The business had revenue of $38.00 million for the quarter. National Research had a return on equity of 47.79% and a net margin of 20.84%.

National Research Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 29th will be issued a dividend of $0.12 per share. The ex-dividend date is Wednesday, March 27th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.36%. National Research's payout ratio is 38.40%.

Institutional Trading of National Research

A number of institutional investors have recently modified their holdings of NRC. BlackRock Inc. raised its holdings in shares of National Research by 6.3% during the 2nd quarter. BlackRock Inc. now owns 1,077,811 shares of the company's stock valued at $46,896,000 after buying an additional 63,465 shares during the period. Vanguard Group Inc. raised its stake in shares of National Research by 1.1% during the third quarter. Vanguard Group Inc. now owns 980,693 shares of the company's stock valued at $43,513,000 after purchasing an additional 10,454 shares during the period. Morgan Stanley lifted its position in shares of National Research by 4,323.8% during the fourth quarter. Morgan Stanley now owns 974,253 shares of the company's stock worth $36,340,000 after purchasing an additional 952,230 shares in the last quarter. Conestoga Capital Advisors LLC boosted its stake in shares of National Research by 1.0% in the fourth quarter. Conestoga Capital Advisors LLC now owns 780,806 shares of the company's stock valued at $30,889,000 after purchasing an additional 7,591 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in National Research by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 636,402 shares of the company's stock valued at $25,176,000 after purchasing an additional 7,531 shares in the last quarter. Hedge funds and other institutional investors own 47.26% of the company's stock.

About National Research

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.